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Abstract
Dysfunctional gap junctions caused by GJB2 (CX26) and GJB6 (CX30) mutations are implicated in nearly half of
nonsyndromic hearing loss cases. A recent study identified a heterozygous mutation, c.119C.T (p.A40V), in the GJB6 gene
of patients with nonsyndromic hearing loss. However, the functional role of the mutation in hearing loss remains unclear. In
this study, analyses of cell biology indicated that a p.A40V missense mutation of CX30 causes CX30 protein accumulation in
the Golgi body rather than in the cytoplasmic membrane. The tet-on protein expression system was used for further study
of mutant proteins in CX30 and CX30A40V co-expressions and in CX26 and CX30A40V co-expressions. The p.A40V missense
mutation exerted a dominant negative effect on both normal CX30 and CX26, which impaired gap junction formation.
Moreover, computer-assisted modeling suggested that this p.A40V mutation affects the intra molecular interaction in the
hydrophobic core of Trp44, which significantly alters the efficiency of gap junction formation. These findings suggest that
the p.A40V mutation in CX30 causes autosomal-dominant nonsyndromic hearing loss. These data provide a novel molecular
explanation for the role of GJB6 in hearing loss.
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Introduction
Hearing loss is a common sensory disorder in humans [1] and
most auditory system dysfunctions resulting in hearing loss are
genetically inherited [2]. The estimated incidence of congenital
hearing loss is 1 in 1000 births, of which approximately 60% are
attributable to genetic factors [3–4].
The inner ear consists of the hearing organ, the cochlea, are
essential for hearing in the mammalian inner ears. The function of
cochlea is dependent on tightly controlled ions, particularly K
+
ions, main charge carrier for sensory transduction [5]. Ultrastruc-
tural studies have identified two gap junction networks, including
that of the epithelial tissue and that of the connective tissue, in the
mammalian cochlear duct and vestibular system [6,7]. The gap
junction system is the most likely pathway for cochlear K
+
recirculation [6,8,9]. In the cochlea, connexin loss in gap junction
complexes disrupt potassium recycling from the synapses at the
base of hair cells through the supporting cells and fibroblasts back
to the high potassium-containing endolymph of the cochlear duct.
The resulting hearing loss is caused by local potassium intoxication
of the Corti’s organ [6].
Gap junction [GJ] channels mediate direct cell-to-cell commu-
nication by enabling intracellular transport of small biological
molecules (,1 kDa), including electrolytes, second messengers and
metabolites [10,11]. The GJ channels have diverse functions,
including electrical signal propagation, metabolic cooperation,
growth control, spatial buffering of ions, and cellular differentia-
tion [12]. The connexins (CXs/Cxs) are a family of proteins that
form GJ channels in vertebrates. The human and mouse genomes
contain twenty-one and twenty connexin genes, respectively [5].
The GJ channels formed by the head-to-head docking of two half
channels, termed connexon, create hydrophilic pores across the
membranes of two contact cells [13]. Each connexon is composed
of six CX protein subunits [14]. The CXs/Cxs within a connexon
may be similar (homomeric) or different (heteromeric), and the
docking of two connexons may also be similar (homotypic
junctions) or different (heterotypic junctions) [15]. Studies also
indicate that CXs/Cxs can assemble into functional hexameric
connexons in the ER membrane [16]. Subcellular fractionation
studies and immunocolocalization analyses suggest that CXs/Cxs
pass through the Golgi apparatus before reaching the plasma
membrane [17–19].
Intercellular communication via gap junctions is crucial for
auditory function. The important role of intercellular communi-
cation, particularly that between GJB2 and GJB6 (encoding CX26
and CX30), has been confirmed by evidence that certain connexin
gene mutations cause sensorineural hearing loss [5,20–23]. The
GJB6 gene (AJ005585) encodes a 261-amino acid protein. The
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and 76% identity with human CX26. Northern blot, RT-PCR,
and in situ hybridization analyses have revealed mouse Gjb6
expression in the trachea, thyroid, brain, and cochlea [21].
Immunocytochemistry studies of a 22-week-old human embryo
have also revealed CX26 and CX30 in the lateral wall of the
cochlea [24]. Recently published data suggest that no gross
developmental defects in cochlear morphology are detected in
both Cx26 and Cx30 mutant mice, but difference is the effect on
the EP generation between the Cx26 and Cx30 mutant mice. In
addition, the paper also indicate that Cx26 seems to be essential
for survival and function of the organ of Corti, but is not required
for its normal development. Therefore, two cochlear GJs, CX26
and CX30, were suggested do not play essential roles in cochlear
development [25]. In some populations, GJB6 mutations, in-
cluding DFNB1 and DFNA3, reportedly cause hearing loss
[21,26–28]. The GJB6 deletion mutation del(GJB6-D13S1830)
has been associated with hearing loss in nine countries [29].
However, the deletion mutation has not been detected in patients
of Taiwan with nonsyndromic hearing loss in our previous study.
In contrast, we identified one heterozygous missense variant,
c.119C.T(p.A40V), and two heterozygous silent variants,
c.261A.T (p.P87P) and c.396G.A (p.L132L) [22]. Presently,
however, the functional alteration of CX30 caused by the variant
GJB6 gene remains unclear. To elucidate the pathogenic role of
CX30 variant in nonsyndromic hearing loss, the functional
properties of variant CX30 gap junctions must be clarified. This
study therefore investigated the effect of the p.A40V (c.119C.T)
variant on functional properties and on the subcellular localization
of the heterozygous variant CX30 protein in HeLa cells and in tet-
on HeLa cells.
Materials and Methods
Molecular cloning of wild-type and mutant GJB6 gene
The mammalian expression vector pcDNA3.1-CT used in this
study was constructed as previously described [30–31]. The open
reading frames (ORFs) of GJB6 were obtained from the genomic
DNA using the PCR reaction. PCR was carried out with the
following oligonucleotide primers: forward primer was GJB6 F-
HindIII 59- atgaagcttatggattgggggacgctg-39 and corresponded to
nucleotides 1–18 of the human GJB6 coding region; reverse
primer was GJB6 R-Xho1 59- atgctcgaggcgcttgggaaacctgtgattg -
39 and corresponded to nucleotides 762–783 of the human GJB6
coding region. The PCR DNA product (801 bp) of the human
GJB6 coding region without stop coden was cloned into the
pcDNA3.1-CT vector. Mutant CX30 gap junction proteins were
obtained by performing oligonucleotide-directed mutagenesis
using the Stratagene Quickchange site-directed mutagenesis kit
(Stratagene,La Jolla,CA). The following oligonucleotide primers
(mutated nucleotide is underlined) were used to prepare the
mutant CX30A40V gene: CX30A40V sense 59- ctagtggtggctgtc-
caggaagtgtggg -39; CX30A40V antisense 59- cccacacttcctgga-
cagccaccactag -39. For fusion protein generation, cDNA sequences
of the autofluorescent reporter proteins EGFP (pEGFPN1 vector;
Clontech, Palo Alto, CA) and DsRed (pDsRedN1 vector;
Clontech, Palo Alto, CA) were fused in-frame to the C-terminus
of WT and mutant CX30A40V. The open reading frames (ORFs)
of GJB6 were obtained from the pcDNA3.1-CT clone after
digestion with HindIII and SacII, and then subcloned into the
HindIII and SacII restriction sites in vectors pEGFPN1 and
pDsRedN1 (Clontech, Palo Alto, CA, USA). Further, the coding
region of CX30WT and that of mutant CX30A40V were
amplified from plasmids containing the CX30 cDNA
(CX30WT-EGFP or CX30A40V-DsRed) using two pair primers
containing recognition sequences 59- SalI (atggtcgactgatcagttatc-
tagatccgg and 39- NotI (atggcggccgcgctagcgctaccggactc) or 59-NheI
(agatccgctagcgctaccg) and 39-EcoRV (atggatatcccgctacaggaa-
caggtgg), respectively, and Platinum Pfx DNA polymerase
(Invitrogen, Carisbad, CA). Purified products were subcloned into
the corresponding site of the bi-directional expression vector pBI
(Clontech, Palo Alto, CA). The dideoxy DNA sequencing method,
using a DNA Sequencing Kit (Applied Biosystems Corporation,
Foster city, CA), an ABI Prism 3730 Genetic Analyzer (Applied
Biosystems Corporation, Foster city, CA), and restriction digest
were used to confirm the DNA sequence of all constructs.
Expression of CX30 gap junction proteins in HeLa cells
Human epitheloid cervix carcinoma cells (HeLa, ATCC CCL
2; American Type Culture Collection, Rockville, MD, USA)
lacking the GJIC gene were used throughout this study. Cell lines
were maintained in standard cell culture medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, and 50 units/
mL penicillin–streptomycin. Cell cultures were maintained at
37uC in a humidified 5% CO2 incubator. The vectors pcDNA3.1-
CT, pGFPN1, and pDsRedN1 containing the DNA fragment
encoding the wild-type or mutant CX30 protein were transfected
to HeLa cells using lipofectAMINE (Invitrogen Corporation,
California, USA). The post-transfection cell line was used for the
subsequent functional analyses.
Transfection and expression of CX30WT, CX30A40V,
CX30WT/CX30A40V and CX26WT/CX30A40V chimerae
protein in tet-on HeLa cell line
The tet-on HeLa cell line deficient in the GJIC gene was
purchased from BD Biosciences Clontech (Palo Alto, CA, USA)
and maintained in Dulbecco’s modified Eagle’s medium, supple-
mented with 10% FBS (Gibco BRL, Gaithersburg, USA),
100 m‘‘Insert.Symbol’’g/ml G418, 100 U/ml penicillin, and
100 m‘‘Insert.Symbol’’g/ml streptomycin at 37uC in a moist
atmosphere containing 5% CO2. Transfection was carried out
using LipofectAMINE reagent (Invitrogen, Carlsbad, USA)
according to the manufacturer’s instructions. A ratio of 1 m‘‘In-
sert.Symbol’’g DNA vs. 2 m‘‘Insert.Symbol’’l LipofectAMINE
2000 was used for the tet-on HeLa cells. Cells were harvested at
24 h post-transfection and grown on a coverslip for 24 h at 37uC
in a humidified 5% CO2 incubator. Then, tet-on HeLa cells were
treated with 1 m‘‘Insert.Symbol’’g/ml doxycyclin (Dox) (Sigma-
Aldrich Corporation, St. Louis, Mo) in cell culture medium to
induce CX26WT, CX30WT, CX30A40V or both WT and
mutant protein expression.
Immunofluorescence staining of post-transfection HeLa
and tet-on HeLa cells
Wild-type or mutant CX protein expression in HeLa and tet-on
HeLa cells was analyzed by a direct fluorescent protein fusion
method involving fusion of EGFP or DsRed to the C-terminal
ends of the CX proteins. Briefly, post-transfection HeLa cells and
tet-on HeLa cells grown on coverslips were fixed with 4%
paraformaldehyde in 0.1 M PBS for 20 min and then rinsed three
times in PBS. The tet-on HeLa cells grown on coverslips were
exposed to Dox for 5 h prior to fixation. Then, the coverslips were
immersed in 10% normal goat serum and 0.1% Triton X-100 for
15 min. The primary antisera and dilutions were as follows: mouse
anti-pan-cadherin antibody at 1:200 (anti-CH19; abcan) for cell
membrane and mouse anti-Golgin-97 at 1:200 (Invitrogen,
Carisbad, CA) for Golgi apparatus. After incubation with primary
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times before adding Alexa Fluor 488 and/or Alexa Fluor 594
conjugated secondary antibodies (Invitrogen, Carisbad, CA).
Endoplasmic Reticulum (ER) was stained with ER-TrackerH
Blue-white DPX Probes at 1:670 dilution (Invitrogen, Carisbad,
CA) for 10 min at room temperature. The nuclei of cells were
counterstained with 49-6-Diamidino-2-phenylindole (DAPI;
2 m‘‘Insert.Symbol’’g/ml) or propidium iodide (PI; 1 mg/ml;
1:400 dilution) for 5 min and rinsed with PBS. Mounted slides
were visualized and photographed using a fluorescence micro-
scope (Zeiss Axioplam, Oberkochen, Germany). All immunoflu-
orescence cell experiments were performed more than five times
and observed more than 200 pairs coupling cells per times with
similar results in the study.
Model building and Structural-based analysis
Although a detailed model of the crystalline structure of human
CX30 is still unavailable, its closest homologous protein family
member, human CX26 gene (amino acid identity 77%), which has
been elucidated by crystallography (PDB entry 2ZW3) to
a resolution of 3.5 A ˚, provides a suitable template [32]. Three-
dimensional (3D) modeling of the human wild type and A40V
mutation were performed using SWISS-MODEL, an automated
homology modeling program. The homology-modeling server
SWISS-MODEL is directly accessible at http://swissmodel.
expasy.org/workspace/ [33,34]. This study used the automatic
modeling approach to apply the complete protein sequence of
human Cx30, including its 261 amino acids and its mutation,
which are available in NCBI GenBank (NP_006774.2) in FASTA
format. For confirmation of energy criteria and for quality
assessment of these protein models, anolea mean force potential
was calculated to determine the energy of interactions indicated by
the non-local environment of heavy atoms in protein chains [35].
Data obtained by the homology models were visualized using
Accelrys
TM ViewerLite version 4.2.
Results
The topological model based on the UniProtKB/Swiss-Prot
O95452 (CXB6_HUMAN) database showed that the CX30
protein subunit, like other CX proteins, contains a short
cytoplasmic amino-terminal domain (NT; amino acid 1–22), four
transmembrane domains TM; TM1 (amino acid 23,45), TM2
(amino acid 76,98), TM3 (amino acid 132,154), and TM4
(amino acid 155,192), which is separated by one cytoplasmic loop
domain (CL; amino acid 99–131) and two extracellular loops (E1;
amino acid 46–75 and E2; amino acid 155–192), and a carboxyl-
terminal cytoplasmic domain (CT; amino acid 216–261). Accord-
ing to above predictive results, we extrapolated that the p.A40V
substitution localized on the putative TM1 domain near the outer
membrane (Figure S1).To clarify the roll of p.A40V, Biology
WorkBench CLUSTAL W (1.81) Multiple Sequence Alignments
(http://workbench.sdsc.edu/, San Diego Supercomputer Center)
was used to compare amino acid sequences of Cx30 among the
b ‘‘Insert.Symbol’’ group in the human CX family. The
comparison revealed that p.A40 residue of CX30 protein was
highly conserved among the human b ‘‘Insert.Symbol’’ group of
the examined CX family members (Fig. 1). A basic ConSeq
analysis system (http://conseq.tau.ac.il/) was also used to study
amino acid sequences of CX30 in the CX gene family of all
species. After the protein sequence of CX30 was deposited, the
system automatically detected homologous sequences of CX30
and conducted multiple alignments. Of the 114 PSI-BLAST hits
obtained by the system, 96 were unique sequences. In the next
step, the system automatically calculated the 50 sequences with the
lowest E-values. The calculation results revealed that p.A40 is
highly conserved (Conseq score=9) and buried in the CX protein
(Figure S2). Therefore, mutation of the p.A40 residue may
interfere with the normal function of CX30 protein and may play
an important role in gap junction channel formation.
To test the effects of p.A40V on the functional properties and
subcellular localization of the CX30 protein, lipofection was used
to transiently transfect gap junction-deficient HeLa cells with
cDNA constructs of wild-type (CX30WT-GFP) or mutant CX30
(CX30A40V-GFP). In cells transiently expressing CX30WT-
EGFP, gap junction plaque formation was indicated by WT
CX30 expression localized to the cell membranes at points of
contact between adjacent GFP-expressing cells. This membrane
localization was confirmed by colocalization with pan-Cadherin
(Fig. 2A). Similarly, CX30WT-DsRed was localized to the cell
membrane (Fig. 2B). In contrast, the impaired trafficking of
CX30A40V to the cell membrane resulted in cytoplasm
concentrations near the nucleus (Fig. 2C). To identify the
organelles in which the cytoplasm of the mutant p.A40V of
CX30 had localized, this study then analyzed HeLa cells
transfected with CX30A40V cDNA using immunostaining with
markers for Golgi apparatus and endoplasmic reticulum (ER)
(Fig. 2D and 2E). The analytical results indicated that most
accumulation of p.A40V of CX30 mutant proteins were in the
Golgi apparatus (Fig. 2D). Some proteins exhibited a reticular
Figure 1. Alignment of amino acid sequences of the TM1 domain of CX30 proteins in members of the human b ‘‘Insert.Symbol’’-
group of CX family. The p.A40 residue, which was mutated in this study, is indicated in bold type. This alanine (A) at codon 40 is identical among
members of human b ‘‘Insert.Symbol’’-group of CX family. Human CX30 is indicated by an asterisk (*).
doi:10.1371/journal.pone.0021473.g001
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21473Figure 2. Analysis of CX30WT and CX30A40V expression in HeLa cells transiently transfected by immunocytochemistry.
Fluorescence microscopy results for CX30WT-EGFP (A) and CX30WT-DsRed (B) HeLa cells showing expression of CX30 fusion protein in the plasma
membranes using pan-cadherin antibody. The CX30A40V-EGFP (C) transfected HeLa cells show impaired trafficking and concentration near the
nucleus. Intercellular localization of mutant CX30A40V protein. Photomicrographs of HeLa cells transiently transfected with CX30A40V-EGFP cDNA
and immunostained for use as markers of Golgi apparatus (D) and ER (E). The staining results for mutant CX30A40V showed substantial co-localization
in the Golgi apparatus and moderate co-localization with ER marker. Cells were counterstained with DAPI to highlight the nuclei. Arrows indicate
CX30 protein localization. Scale bars: 10 m‘‘Insert.Symbol’’m.
doi:10.1371/journal.pone.0021473.g002
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probe, an endoplasmic reticulum marker (Fig. 2E). In addition,
these finding are consistent with our previous observation of
subcellular localization of the CX30 protein using FlAsH-EDT2
labeling reagent and CX30 antibody (unpublished data; Figure
S3).
Our previous study found that p.A40V of CX30 is a heterozy-
gous mutation in patients with hearing loss [22]. Thus, co-
expression studies were performed to test the effects of mutant
proteins on CX30WT in tet-on HeLa cells. For this test, a bi-
directional tet-on protein expression system was used with equal
amounts of the two respective expression proteins. Cells expressing
both CX30WT-DsRed and the CX30WT-EGFP protein exhib-
ited co-assembly expression in the cell membrane of tet-on HeLa
cells (Fig. 3A). Conversely, both CX30WT-RFP and the
CX30A40V-EGFP mutant revealed expression patterns resem-
bling those of p.A40V alone (Fig. 3B). Analytical results revealed
co-assembly of CX30A40V mutant protein and CX30WT
protein, resulting in impairment of CX30WT protein trafficking
to the cell membrane.
Reports of CX30 and CX26 co-expression in the inner ear
[2,24,36–37] prompted further tests of the effects of the mutant
CX30A40V protein on CX26WT by using the tet-on protein
expression system. Both CX30WT-DsRed and CX26WT-EGFP
Figure 3. Co-expression of mutant proteins with CX30WT and CX26WT revealed by tet-on protein expression system. (A) Tet-on HeLa
cells co-expressing CX30WT-DsRed and CX30WT-EGFP. Co-localization of the two proteins is visible at the plasma membrane. (B) Tet-on HeLa cells co-
expressing CX30WT-DsRed and CX30A40V-EGFP. Co-localization of the two proteins is visible near the nucleus regions. (C) Tet-on HeLa cells co-
expressing CX30WT-DsRed and Cx26WT-EGFP. Co-localization of the two proteins is visible at the plasma membrane. (D) Tet-on HeLa cells co-
expressing CX26WT-DsRed and CX30A40V-EGFP. Co-localization of the two proteins is visible near the nucleus. Arrows indicate co-expressed
proteins. Cells were counterstained with DAPI to highlight the nuclei. Scale bars: 10 m‘‘Insert.Symbol’’m.
doi:10.1371/journal.pone.0021473.g003
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HeLa cells (Fig. 3C) which confirmed that both CX26 and CX30
can be trafficked to the same gap junction plaque. However, co-
expression of CX30A40V-EGFP and Cx26WT-DsRed changed
the localization of these CX26WT proteins from the cell
membrane to the cytoplasm (Fig. 3D). Analytical results revealed
co-assembly of CX30A40V mutant protein and CX26WT protein
and impaired CX26WT protein trafficking to the cell membrane.
We therefore hypothesized that p.A40V of CX30 has a dominant
negative effect on CX30WT and CX26WT.
To further study the protein-level mechanisms of the p.A40V
mutation, a 3D model was constructed for a bioinformatic
structural analysis. The analytical results found that the highly
conserved residues in this region, including Ala39, Ala40, Val43
and Ile74, comprise a hydrophobic core around Trp44, which
stabilizes the CX30 intra-molecular antiparallel organization of
the helical structure between transmembrane domain 1 (TM1) and
TM2 (Fig. 4). At codon 40 (p.A40V), therefore, a substitution of
small side chain ‘‘alanine (A)’’ by long side chain ‘‘valine (V)’’
destroys the intra-molecular structure of the WT CX30 protein
(Fig. 4B). Anolea mean force potential energy was also applied in
the final models to compare the energy criteria with the energy
change in mean force derived from mutation CX30 structure
(Fig. 5). The force potential energy was changed at residues 36–42
and 71–77 located on TM1 and TM2. Based on these results, we
suggest that p.A40 plays an important role in CX30 protein.
Specifically, mutant p.A40V causes a loss of function in CX30
protein.
Discussion
For auditory function, the important role of intercellular
communication via gap junctions has been confirmed by findings
that certain CX gene mutations, particularly those of GJB2 and
GJB6, cause hearing loss [38]. Studies of populations in Spain and
[27] and elsewhere [29,39] indicate that a 342-kb deletion in GJB6
is the second most common cause of genetic deafness. A 309-kb
deletion has also been reported in the GJB6 gene of hearing loss
patients [40]. In contrast, most studies agree that the proportion of
point mutations is smaller than that of deletion mutations. One
point mutation, c.14C.A (p.T5M), in the GJB6 (CX30) is known
to be involved nonsyndromic deafness by dominant inhibition of
the activity of wild-type GJB6 in normal channels, underlining the
critical function of GJB6 in normal hearing [21].Although none of
the above mutations were observed in our previous study, we
identified a missense heterozygous mutation, c.119C.T (p.A40V)
of GJB6, in the patients with nonsyndromic hearing loss [22]. The
biogenesis of gap junction intercellular communication channels
involves a process leading to the formation of a hexameric
connexon hemichannel embedded in the plasma membrane that
docks with a connexon in the membrane of a neighbouring cell
[41]. In addition, CX mutations can be divided into three
categories: group 1 mutations, which only minimally affect normal
protein function; group 2, which can alter communication,
especially electrophysiological properties of gap junctions; and
group 3, which are functionally deficient owing to major
trafficking or targeting abnormalities of the connexins [42].
Figure 4. Bioinformatic estimation of three-dimensional (3D) structure of wildtype and p.A40V CX30 protein. Comparison of protein
secondary structure architectures reveals the intra-molecular interactions between wild type (A) and A40V mutation (B) in monomeric human CX30.
Secondary structures appear as red solid cylinders (a-helices), blue arrows (b-sheets) and white loops (turns). The yellow boxes indicate the close-up
views of intra-molecular interactions focus on the extracellular part (E1) of the transmembrane region (TM2) in a similar orientation as in ball and stick
representation. The highly conserved residues in this region, including Ala39, Ala40, Val43 and Ile74, contributed to the hydrophobic core around
Trp44, which stabilized the Cx30 intra-molecular structure.
doi:10.1371/journal.pone.0021473.g004
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affect any one or more of these processes. In this article, we have
been demonstrated that the missense mutation is belong to group 3
mutation that are functionally deficient owing to trafficking
abnormalities.
This study found that the p.A40 residue of CX30 is located at
the first transmembrane domain (TM1) and is identical among the
human b group of the CX protein family and throughout the
evolution of all species. The M1 domain may be a pore-forming
domain [43] that is essential for transporting CX protein into
plasma membrane [44]. The p.A39V, p.A39P and p.A40V of
GJB1 mutant have positions similar to those of the GJB6 p.A40V
mutant located at the first transmembrane region and are retained
in the ER (p.A39V, p.A39P) or in the Golgi (p.A40V) in HeLa
cells [45,46]. Disease-associated mutations in GJB2 whose
positions coincide with p.A40V of GJB2 have also been detected
in the keratitis ichthyosis deafness (KID) syndrome. [47]. Our data
indicated that the p.A40V mutant protein of CX30 was retained
in the Golgi apparatus of HeLa cells. Moreover, we observed
significant inhibition of the functional activity of CX30-WT in
HeLa cells when expressed in a manner mimicking a heterozygous
genotype. Thus, p.A40V mutation has dominant negative effect on
the function of WT CX30. Based on above findings, we suggested
that the p.A40 amino acid likely plays a critical role in CX30, and
as a result a mutation in this residue will lead to loss of function of
the protein.
Mouse studies suggest that Cx26 (Gjb2) and Cx30 (Gjb6) are the
two most abundantly expressed Cxs in the mouse cochlea
[6,37,48]. In the inner ear, Cx26 and Cx30 share similar protein
structures, expression distribution patterns, and colocalizations of
two Cx isoforms within the gap junction plaques [48–50]. Some
GJB2 gene mutations exert a selective transdominant inhibitory
effect on the function of other connexins, including Cx30, that are
preferentially expressed in the epidermis, skin appendages, the
cornea and in deafness [36,51]. Similarly, our co-expression study
found that CX30-A40V mutant trafficking defects could not be
rescued by co-expression with CX26-WT; instead, the p.A40V of
the CX30 mutant causes loss of function in the WT CX26 protein.
Therefore, we hypothesize that the p.A40V missense mutation has
a trans-dominant negative effect. To date, no studies have shown
that Cx30 mutations have trans-dominant inhibitory effects on the
function of other connexins. This co-expression study is the first
evidence that p.A40V of the CX30 mutation has a trans-dominant
negative effect on CX26.
Improved 3D characterization of protein structures is needed to
clarify the functions of proteins and their disease formation
relationships [33,52]. High-resolution characterization of proteins
can be provided by either experimental methods such as X-ray
crystallography and nuclear magnetic resonance or by computa-
tional analysis [52]. However, the number of known protein
sequences far exceeds that of experimentally solved protein
structures. In the absence of crystallographic structures, a variety
of advanced homology modeling methods have been developed,
which can provide reliable models of proteins that share 30% or
more sequence identity between known structures and target
proteins [33,34]. Homology modeling is currently the most
accurate computational method to generate reliable structural
models and is routinely used in many biological applications [34].
Figure 5. Plot outputs of Anolea mean force potential reported from SWISS-MODEL workspace. The graphs present the computer
modeling results for wild-type (A) and p.A40V mutations (B) of the CX30 protein. Relative quality was evaluated by target-template similarity and
modeling procedure. Non-local environments of each residue in the human Cx30 gene model (x-axis) were based on the template gene human Cx26
protein and on the percentage of energy change in all pairwise non-local interaction energy values between the template and modeling structure
(represented by y-axis). Negative scores are plotted downwards and upwards to further validate the model by indicating the favorable and
unfavorable energy environments, respectively. The arrows and boxes indicate that the two conserved regions contributing to the hydrophobic core
around the key amino acid Trp44 were residues 36–42 located in the transmembrane 1 (TM1) region and residues 71–77 located in the TM2 region of
the human Cx30 proteins, respectively.
doi:10.1371/journal.pone.0021473.g005
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interpreting sequence variations and for designing mutagenesis
experiments to elucidate the biological functions of proteins
[53,54]. The crystalline structure of the gap junction channel
formed by human CX26 has also been reported recently. The
paper was shown that eight key residues (V43, W44, A39, A40,
I74, W77, F154 and M195) have intra-protomer interactions
within two hydrophobic cores of CX26 protein and stabilize the
CX26 connexin structure [32]. In the clinical data, mutations of
these residues are associated with deafness and skin diseases [55].
The pore-lining residues of CX26 at the TM1/E1 boundary are
K41, E42 and G45 [32]. In the study, we compared above eight
key residues of CX26 at two hydrophobic cores with CX30 results
in identical between CX26 and CX30. Further, using a simulated
model with human Cx26 protein (PDB ID is 2ZW3) as a template
and an automatic SWISS-MODEL homology modeling program,
this study found that the A40 of CX30 in the first hydrophobic
core, not in the pore region, around Trp44 stabilizes the CX30
intra-molecular antiparallel helical structure between transmem-
brane segment 1 (TM1) and TM2. In previous paper indicated
that most of the residues involved in intra-protomer interactions
are conserved within the connexin family and mutations probably
interfere with the proper folding and/or oligomerization of
connexins, thus resulting in defective channels [32]. Therefore,
our results of prediction obtained by homology modeling methods
can elucidate functional deficiencies observed in immunofluores-
cence experiments, which is p.A40V missense mutation of CX30
caused CX30 protein accumulation in the Golgi body rather than
in the cytoplasmic membrane.
Recently, there are reported to indicate that the mutations,
p.A40V of CX26, which is positioned near the TM1/E1 boundary
and are associated with the keratitis ichthyosis deafness (KID)
syndrome. The mutants have been reported to form hemichannels
that open aberrantly, leading to ‘‘leaky’’ cell membranes and show
significantly impaired regulation by extracellular Ca
2+, increasing
the likelihood of aberrant hemichannel opening [56]. However, our
result found that the dominant effect exerted by CX30 p.A40V
mutation,whichisdramaticallydifferentwithp.A40VofCX26.We
compared pore-lining residues of CX26 at the TM1/E1 boundary
with CX30 results in the residue of p.41 from K (Lys) into Q (Gln)
between CX26 and CX30. The residue of K41 creates a narrowed
part of the pore with the diameter of about 17Au and is unique to
CX26, generating a more positively charged environment between
the funnel and the following negatively charged part of the solute
pathway [32]. In addition, Cx26 and Cx30 share the same pattern
of expression in the mice cochlea and form homotypic or
heterotypic channels. The trafficking and assembly features of
CX30 are also similar to those of CX26 [50]. Base on the above
results, it will help us to explain the dominant negative effect of WT
CX26 by CX30 p.A40V, which is different molecular machinery in
only CX26 p.A40V mutation. However, these are prediction results
and we only build the ‘‘single unit’’ of the Cx30 3D structure model
based on the CX26 crystal structure [32] in the study. Simulta-
neously, the permeation pathway of a gap junction channel consists
of an intracellular channel entrance, a pore funnel and an
extracellular cavity. Therefore, further X-ray crystallographic
studies are needed to clarify how this mutation affects the crystalline
structure of wild-type and mutant CX30 or CX26 proteins.
Supporting Information
Figure S1 Schematic representation of the domain
structure of the CX30 protein with indication of known
variants. The black star and arrows indicate the c.119C.T
(p.A40V) variant in CX30. M1-4: transmembrane domains; E1-2:
extracellular domains; CL: cytoplasmic linking domain; N: N-
terminal domain; C: C-terminal domain. [This figure was
modified from Figure 4 in the text entitle ‘‘Attachment, polarity
and communication characteristics of bone cells’’ by Ilvesaro J.
(2001).]
(TIF)
Figure S2 ConSeq predictions demonstrated on human
CX30 [SWISS-PROT: O95452 (CXB6_Human)], using 50
homologues obtained from the Pfam database (family
code: PF00029). The sequence of the CX30 protein is displayed
with the evolutionary rates at each site colour-coded onto it (see
legend). The residues of the Cx26 sequence are numbered starting
from 1. The first row below the sequence lists the predicted burial
status of the site (i.e. ‘‘b’’—buried versus ‘‘e’’—exposed). The
second row indicates residues predicted to be structurally and
functionally important: ‘‘s’’ and ‘‘f’’, respectively. Vertical arrows
indicate amino acid codons (p.A40).
(TIF)
Figure S3 Expression analysis of CX30WT and
CX30A40V in transiently transfected HeLa cells using
the FlAsH
TM-EDT2 Labeling Kit (A) and anti-CX30
antibody (B, C). (A, B) Fluorescence microscopy of CX30WT
HeLa cells shows expression of the wild-type protein in the plasma
membranes. (C) In contrast, CX30A40V transfected HeLa cells
show expression of the mutated protein near the nucleus. Arrows
indicate expression of CX30 protein. Scale bars: 10 mm.
(TIF)
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